Landmark BioVentures AG, founded in 2021 and headquartered in Basel, Switzerland, is an integrated and agile biotech hub-and-spoke company.
LBV takes a unique model focused on lean operations, smart capital allocation, and diversified nexus of 8 companies developing 12 first-in-class therapeutics.
Some insights
We accelerate preclinical-stage therapies toward patients in high-unmet-need areas — fibrosis, oncology, CNS, ophthalmology — by sharpening science into investable assets. Fewer failed trials, faster capital deployment, more lives improved.
We built rigorous frameworks — 5R+Three Pillars, Asset/Equity Story, Claim Engine — that transform raw science into credible, fundable programs. We operate with Swiss precision and genuine care for the founders and patients behind each asset.
RA Capital, Debiopharm and Atlas Venture for thesis-driven conviction at preclinical stage. Roivant and Bridgebio for translational rigor. Roche and AstraZeneca's R&D leadership for institutionalizing the 5R framework — proving that discipline, not luck, drives drug development success.
Strengths: strategic drug development, investor narrative, translational science, operational frameworks. Future needs: clinical operations leadership, regulatory strategy, and AI-augmented data analytics to sharpen our R&D intelligence platform.
"You help small science companies explain why their medicine matters — and find the people willing to fund it." Essentially: translating hope into credible stories, and credible stories into capital that moves drugs forward.
Earlier-stage risk appetite from Swiss and European investors, stronger bridge between ETH/EPFL spinouts and Series A capital, and more structured platforms for preclinical BD dialogue — so promising assets don't stall before proof-of-concept.
Specialist biotech VCs (EU/US), pharma BD heads in our therapeutic areas, clinical KOLs for advisory roles, Swiss accelerators and Innosuisse networks, and family offices with life science mandates open to preclinical risk.
